All stocks / BCAB
BioAtla, Inc. BCAB
BioAtla (BCAB): financing deals mentioned in an 8-K in October 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- BIOATLA INC
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 16
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($59,607,000)
It spends more than it earns
Under strainThe company lost $59.6 million in the year. It reported no sales.
- Cash and cash equivalents
- $7,118,000
- Net cash used in operating activities
- ($48,204,000)
The cash could run out soon
Under strainIt had $7.1 million in the bank and used about $4 million a month. At that pace the money lasts about 2 months unless it borrows or sells more shares.
- Total assets
- $13,828,000
- Total liabilities
- $50,017,000
It owes more than it owns
Under strainEverything the company owns adds up to $13.8 million. Its debts and unpaid bills add up to $50 million. That is about $3.62 owed for every $1 owned.
What this adds up to
3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
8-K filed 2026-10-20 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Estimated float about 1,250,983 shares as of 2026-09-30: 1,668,261 outstanding minus 417,278 held by 4 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-03-02 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-02-06 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-01-30 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-01-12 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2025-12-30 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2025-11-21 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about BCAB
Does BCAB file reports with the SEC?
Yes. BioAtla files with the SEC under company number 0001826892. The most recent filing we hold is a 10-Q dated 2026-11-16.
Source recordHow many BCAB shares are outstanding?
1,668,261 shares as of 2026-09-30, as reported to the SEC.
Source recordHas BCAB filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs BioAtla?
Officers named in its insider filings: Jay M Phd Short (Chief Executive Officer), Eric Sievers (Chief Medical Officer) and Christian Vasquez (Chief Financial Officer).
Source recordIs BioAtla making money?
The company lost $59.6 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record